Resources

Resources for Medical Professionals

American College of Rheumatology. https://www.rheumatology.org/I-Am-A/Rheumatologist

American Society for Bone and Mineral Research. https://www.asbmr.org/Default.aspx

Arthritis Foundation. https://www.arthritis.org/

Clinical Immunology Society. https://clinimmsoc.org/CIS.htm

ClinicalTrials.gov. https://www.clinicaltrials.gov/

National Institute of Arthritis and Musculoskeletal and Skin Diseases. https://www.niams.nih.gov/

National Psoriasis Foundation. https://www.psoriasis.org/for-medical-professionals/

Treatment Recommendations

Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis. Arthritis Rheumatol. 2016;68:1060-1071. https://pubmed.ncbi.nlm.nih.gov/26749174/

Mikuls TR, Johnson SR, Fraenkel L, et al. American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 2. Arthritis Rheumatol. 2020;72:e1-e12. https://pubmed.ncbi.nlm.nih.gov/32734689/

Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020;59(suppl 1):i37-i46. https://pubmed.ncbi.nlm.nih.gov/32159790/

Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71:5-32. https://pubmed.ncbi.nlm.nih.gov/30499246/

Other Journal Articles

Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterol. 2020;159:481-491.e3. https://pubmed.ncbi.nlm.nih.gov/32425234/

Coates LC, Helliwell PS. Psoriatic arthritis: State of the art review. Clin Med (Lond). 2017;17:65-70. https://pubmed.ncbi.nlm.nih.gov/28148584/

Coates LC, Moverley AR, McParland L, et al. Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): A UK multicentre, open-label, randomised controlled trial. Lancet. 2015;386:2489-2498. https://pubmed.ncbi.nlm.nih.gov/26433318/

D’Silva KM, Serling-Boyd N, Wallwork R, et al. Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: A comparative cohort study from a US ‘hot spot’. Ann Rheum Dis. 2020;79:1156-1162. https://pubmed.ncbi.nlm.nih.gov/32457048/

Eder L, Haddad A, Rosen CF, et al. The incidence and risk factors for psoriatic arthritis in patients with psoriasis: A prospective cohort study. Arthritis Rheumatol. 2016;68:915-923. https://pubmed.ncbi.nlm.nih.gov/26555117/

Fredi M, Cavazzana I, Moschetti L, et al. COVID-19 in patients with rheumatic disease in northern Italy: A single-centre observational and case-control study. Lancet Rheumatol. 2020;2:e549-e556. https://pubmed.ncbi.nlm.nih.gov/32838307/

Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalization for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859-866. https://pubmed.ncbi.nlm.nih.gov/32471903/

Gladman DD, Thavaneswaran A, Chandran V, et al. Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease? Ann Rheum Dis. 2011;70:2152-2154. https://pubmed.ncbi.nlm.nih.gov/21914627/

Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015;74:1045-1050. https://pubmed.ncbi.nlm.nih.gov/24525911/

Pablos JL, Galindo M, Carmona L, et al. Clinical outcomes of hospitalized patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: A multicentric matched cohort study [published online ahead of print, 2020 Aug 12]. Ann Rheum Dis. 2020; 218296. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7430185/

Theander E, Husmark T, Alenius GM, et al. Early psoriatic arthritis: Short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA). Ann Rheum Dis. 2014;73:407-413. https://pubmed.ncbi.nlm.nih.gov/23355078/

Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet. 2018;391:2285-2294. https://pubmed.ncbi.nlm.nih.gov/29893227/

Wollina U, Fioranelli M, Goldust M, et al. Psoriatic arthritis and COVID-19 pandemic: Consequences in medical treatment? [published online ahead of print, 2020 Jun 1]. Dermatol Ther. 2020;33:e13743. https://pubmed.ncbi.nlm.nih.gov/32478971/

Dan S, Pant M, Upadhyay SK. The case fatality rate in COVID-19 patients with cardiovascular disease: Global health challenge and paradigm in the current pandemic [published online ahead of print, 2020 Sep 15]. Curr Pharmacol Rep. 2020;1-10. https://doi.org/10.1007/s40495-020-00239-0

Scroll to Top

Updates in the Treatment and Prevention of COVID-19

Casirivimab Plus Imdevimab Authorized for Post-exposure Prophylaxis Against COVID-19

The FDA has authorized the use of casirivimab plus imdevimab for post-exposure prophylaxis in people 12 years of age or older who are at high risk for progression to severe COVID-19. The authorization for the monoclonal antibody cocktail includes people who are not fully vaccinated or are not expected to mount an adequate response to vaccination and have been exposed to a SARS-CoV-2-infected individual or are at high risk of exposure because of infection occurring in the same institutional setting (such as in nursing homes or prisons).

In a phase 3 trial, the cocktail of casirivimab plus imdevimab was found to reduce the risk of symptomatic infections by 81% in those who were not infected when they entered the trial. In a subgroup of patients who met the criteria for high risk of progression to severe COVID-19, there was a 76% reduction in COVID-19 with this combination therapy compared with placebo. Casirivimab plus imdevimab reduced the risk of symptomatic infections by 62% in patients who were asymptomatic, regardless of their infection status. Patients with ongoing exposure may receive repeat dosing of casirivimab plus imdevimab monthly by intravenous infusion or subcutaneous injection.

Multiple analyses have shown that casirivimab plus imdevimab retains potency against the main variants of concerns circulating in the US, including the Delta (B.1.617.2; first identified in India), Gamma (P.1; first identified in Brazil), and Beta (B.1.351; first identified in South Africa) variants.

Reference

FDA. Fact sheet for health care providers. Emergency Use Authorization (EUA) of REGEN-COV™ (casirivimab and imdevimab). July 2021 (www.fda.gov/media/145611/download). Accessed 8/6/2021.